ISRCTN24219839 https://doi.org/10.1186/ISRCTN24219839

Trial of PACEBOM versus CHOP in histologically aggressive non-Hodgkins lymphoma

Submission date 01/07/2001	**Recruitment status** No longer recruiting	[ ] Prospectively registered [ ] Protocol
Registration date 01/07/2001	**Overall study status** Completed	[ ] Statistical analysis plan [X] Results
Last Edited 01/02/2012	**Condition category** Cancer	[ ] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

Protocol serial number
LY3

Study information

Scientific Title

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Primary study design
Interventional

Study design
Randomised controlled trial

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Lymphoma (non-Hodgkins)

Interventions
Patients were randomised to one of two regimens:
1. CHOP Regimen: Multi-drug chemotherapy with cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone (CHOP) repeated every 28 days. A minimum of six courses to be given with two courses beyond the attainment of complete response
2. PACEBOM Regimen: Multi-drug chemotherapy with prednisolone, adriamycin, cyclophosphamide and etoposide (PACE) alternating every 7 days with bleomycin, vincristine and methotrexate (BOM). Six cycles of PACE and five of BOM to be given

Intervention Type
Other

Phase
Not Specified

Primary outcome(s)
Not provided at time of registration

Key secondary outcome(s)
Not provided at time of registration

Completion date
31/10/1992

Eligibility

Key inclusion criteria
1. Aged 16 to 69 years
2. Previously untreated histologically aggressive lymphoma with a large cell component: Diffuse large cell, Diffuse immunoblastic, Diffuse mixed cell
3. Stages II-IV
4. No contraindications to treatment protocols

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Not Specified

Sex

Key exclusion criteria
Patients with Burkitt's and lymphoblastic lymphoma to be excluded

Date of first enrolment
01/11/1987

Date of final enrolment
31/10/1992

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
UKCCCR Register Co-ordinator
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Cancer Research UK (CRUK) (UK)

ROR
https://ror.org/054225q67

Funder(s)

Funder type
Charity

Funder Name
Cancer Research UK

Alternative Name(s)
CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type
Private sector organisation

Funding Body Subtype
Other non-profit organizations

Location
United Kingdom

Funder Name
Lymphoma Research Trust

Funder Name
Lisa Lear Fund

Funder Name
Isle of Man Anti-Cancer Association

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/07/1996		Yes	No